About the MMRF
The MMRF is the largest nonprofit in the world focused on accelerating a cure for each and every multiple myeloma patient. We relentlessly pursue innovations that advance development of novel therapies and more personalized treatment approaches for patients. We identify areas of unmet need and then find solutions to address them, bringing together the right resources and partners to drive better outcomes for the myeloma community.
Our mission
To accelerate a cure for each and every multiple myeloma patient.
Our Culture
Urgency
We move fast. In the battle against cancer, we know time is of the essence — that’s why it’s imperative we work quickly and diligently when it comes to making the best decisions for patients. We streamline communications among partners and share critical data with researchers to accelerate a cure for each and every multiple myeloma patient.
Innovation
We believe in disruption. Curing cancer isn’t about solving problems — it’s about finding transformative solutions that change the way things are done forever. We tackle the big picture — like creating large, accessible clinical datasets — and all the little details — down to individuals’ DNA — to be on the cutting edge of cancer research.
Results
We believe innovative business practices make a big impact — and thanks to the business acumen of our leadership, we are a results-driven organization. We have helped bring 15 multiple myeloma drugs to market and many more are in the pipeline. Clinical trials for myeloma patients were a rare occurrence prior to the MMRF — so we opened over 80 clinical trials. Because of our relentless work in collaboration with our partners and the community, multiple myeloma patient survival rates have increased from 3 years to 10 years.
See how our work is changing cancer research
Meet our leaders
Financials
An extraordinary 90% of the MMRF total budget goes directly into research and related programming, consistently earning us top rankings from the nation’s leading charity evaluators. See our accreditations.
News and press
March 23, 2023
March 23, 2023
After receiving Tecvayli and achieving a complete response, how long should treatment continue and is risk of infection present as long as treatment continues? Bispecific antibody […]
March 15, 2023
March 15, 2023
If you are refractory to one drug in a class, are you automatically refractory to other drugs in that same class? Myeloma patients who become refractory, […]
February 27, 2023
February 27, 2023
What is a second primary malignancy (SPM) and what is a myeloma patient’s risk for developing one while on Revlimid maintenance therapy? SPM is another cancer […]
